The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

The drug, a unique combo of xanomeline and trospium chloride targeting M1/M4 muscarinic receptors, failed to pass the finish line in the ARISE Phase III trial. The study aimed to validate its use as ...

Neurocrine's drug acts as a muscarinic M4 selective agonist, while KarXT targets M1 and M4 receptors and emraclidine is described as a muscarinic M4 receptor-positive allosteric modulator (PAM).

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

mGluR5 receptor is a suitable target to address ... results in a sustained and growing improvement in sensory motor function in comparison to vehicle treatment. Similar improvement in sensory ...

Initially I was studying nicotinic receptors, which-as you can tell from the name-pick up chemical signals from nicotine sources like tobacco, but their primary job is to mediate the responses to ...

Certain common genetic changes might make some people with focal epilepsy less responsive to seizure medications, finds a new global study led by researchers at UCL and UTHealth Houston. Focal ...